Human Papillomavirus DNA TestsNCT02750124
IT-system Development for Reaching Cervix Cancer Screening Non-attenders
A study testing Cobas PCR Female swab sample Packet and Routine practice in people with Human Papillomavirus DNA Tests and Cervical Cancer, run by Karolinska Institutet.
Trial summary
The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period. Read more about this study
- Who is it for?
- Ages 33 to 60 years, women only
- Conditions the study is for
- Human Papillomavirus DNA Tests, Cervical Cancer
- What is being tested?
- Cobas PCR Female swab sample Packet and Routine practice
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8,000 participants
- Where
- No sites listed yet
- Study dates
- 14 Mar 2016to Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 33 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Non-participants in cervical cancer screening during a 10 year period
Who cannot join
- Active refusers
About this study
Official title: IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders
The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period.
Read the detailed description
BACKGROUND Non-participation in the screening program is the main risk factor for cervical cancer (Andrae et al JNCI, 2008). Therefore it is important to reduce barriers to screening and facilitate participation in the screening program for cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations.
Results from a population-based, randomized study in western Sweden concluded that by offering HPV self-sampling kits to screening non-attendees, 17% of cervical cancer cases could be avoided. Offering self-sampling kits to women who have not attended screening in the organized program, can lead to greater participation without substantial increases in the overall health care costs. While there is a growing body of evidence supporting the use of self-sampling, it is unclear how this strategy can be implemented effectively in the context of an organized screening program. An alternative is to offer women the chance to speak with a coordinating midwife who can answer questions and address concerns regarding screening. It is unclear how the results of different research studies should be put into practical use within an organized screening program. Currently, women who have not attended screening are sent an annual reminder invitation. We want to examine whether these alternative strategies (self-sampling and contact with a midwife) may work as well, or better, than current strategy of reminder invitations to non-attenders.
AIM The aim of this randomized health services study is therefore both to test the feasibility of providing alternative strategies instead of the customary reminder invitations to women in Stockholm (so-called feasibility study, primary aim), and whether such strategies will increase overall participation in screening (secondary aim).
STUDY DESIGN AND METHODOLOGY A new IT infrastructure for ordering a self-sampling kit has been developed by LabMed, KI. This in conjunction with the screening database, will be used to identify and invite women who are long-term non-participants in cervical screening. Women who have not participated for ten years, despite annual reminder invitations, will be identified and randomized to one of four strategies.
- A validated HPV self-sampling kit will be sent directly to women with a study invitation letter and instructions.
- An invitation to order an HPV self-sampling kit through an online application will be sent.
- An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent.
- The standard annual reminder invitation will be sent (control, routine practice)
Women who choose to participate will be sampled and monitored according to the standards of care in the regional cancer screening program. HPV-positive women will be followed by colposcopy and biopsy according to standard clinical guidelines. Women will be invited over the course of 3 months. All letters will be printed in advance with pre-marked dates. Batches will be sent out weekly and checked against changes in the population registry data (for individuals that have moved, taken a smear, died, or unregistered, invitation letters will be sorted out and those individuals marked in the database).
2 Notation and abbreviations
- PNR = person nummer, personal ID number 3 Study population 3.1 Inclusion criteria
- Women who have lived in Stockholm for the past 10 years and have been sent annual reminder at least once per year for 10 years without attending screening.
Specific selection process:
Include women without an "H-prov" on record for the past 10 years Include women have actively been sent a reminder invitation (invitation type=1) during 10 years time. In other words, resident in Stockholm for the past 10 years.
Include women over the age of 33 3.2 Exclusion criteria Women who have opted out of the screening program Hysterectomized Return to sender Changed PNR Women who are marked as Expired=1. Women who have reason marked for being unregistered but are not marked as is unregistered=1.
Women who are due to receive their reminder invitation in the next 3 months 4 Statistical analyses Selection of the study population Randomization A random selection of 8000 women will be chosen from all women meeting the study inclusion criteria.
These 8000 women will be randomized to the 4 study arms (age-stratified 30-50 and 51-60).
The selection of the study population and the randomization to study arms will be carried out by Anna Stoltenberg, Statistician at RCC and outside of the study group 1.
Follow-up - study end date 2016-12-31
- Conditions
- Human Papillomavirus DNA Tests, Cervical Cancer
- Being tested
- Cobas PCR Female swab sample Packet, Routine practice
- Keywords
- participation, self sampling, Screening
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cobas PCR Female swab sample PacketDevice
The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
Routine practiceOther
The standard, annual renewed invitation to cervical screening.
| Study group | Role | What they receive |
|---|---|---|
| HPV self sampling test sent | Active comparator | A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured. Receives: Device: Cobas PCR Female swab sample Packet |
| HPV self sampling test ordered | Active comparator | An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured. Receives: Device: Cobas PCR Female swab sample Packet |
| Nurse navigator contact | Active comparator | An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured Receives: Device: Cobas PCR Female swab sample Packet; Other: Routine practice |
| Control | Placebo comparator | The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline. Receives: Other: Routine practice |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of women responding (either by and HPV test or a Pap test)
Participation rate in screening
Measured: From recruitment until end of study on December 31st 2016 (average 8 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2016 (estimated)
- Study start14 Mar 2016
- Primary completion31 Dec 2016
- Study completionDec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Human Papillomavirus DNA TestsStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 8,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Regional Cancer Centre Stockholm Gotland
- Responsible party
- Principal investigator, Joakim Dillner, Karolinska Institutet
- Investigators
- Joakim Dillner, MD, Principal investigator, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02750124
- Sponsor's protocol ID
- NIASC 62721
- Status last verified
- Sep 2020
- First submitted
- 13 Mar 2016
- Last updated
- 5 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided: Our intention is to share data, but a plan for how this will be done in practise has not been written.
Publications
Elfstrom KM, Sundstrom K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Ohman D, Lamin H, Eklund C, Dillner J, Tornberg S. Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. Int J Cancer. 2019 Dec 1;145(11):3033-3039. doi: 10.1002/ijc.32374. Epub 2019 May 10.
PubMed 31032904Andersson S, Belkic K, Mints M, Ostensson E. Acceptance of Self-Sampling Among Long-Term Cervical Screening Non-Attenders with HPV-Positive Results: Promising Opportunity for Specific Cancer Education. J Cancer Educ. 2021 Feb;36(1):126-133. doi: 10.1007/s13187-019-01608-0.
PubMed 31522376
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders
- ClinicalTrials.gov ID
- NCT02750124
- Acronym / sponsor ID
- NIASC 62721
- Conditions
- Human Papillomavirus DNA Tests, Cervical Cancer
- Keywords
- participation, self sampling, Screening
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 8,000 participants (actual)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Regional Cancer Centre Stockholm Gotland
- Study start
- 14 Mar 2016 (actual)
- Primary completion
- 31 Dec 2016 (actual)
- Study completion
- Dec 2021 (estimated)
- First posted
- 25 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period.
Detailed description
BACKGROUND Non-participation in the screening program is the main risk factor for cervical cancer (Andrae et al JNCI, 2008). Therefore it is important to reduce barriers to screening and facilitate participation in the screening program for cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations.
Results from a population-based, randomized study in western Sweden concluded that by offering HPV self-sampling kits to screening non-attendees, 17% of cervical cancer cases could be avoided. Offering self-sampling kits to women who have not attended screening in the organized program, can lead to greater participation without substantial increases in the overall health care costs. While there is a growing body of evidence supporting the use of self-sampling, it is unclear how this strategy can be implemented effectively in the context of an organized screening program. An alternative is to offer women the chance to speak with a coordinating midwife who can answer questions and address concerns regarding screening. It is unclear how the results of different research studies should be put into practical use within an organized screening program. Currently, women who have not attended screening are sent an annual reminder invitation. We want to examine whether these alternative strategies (self-sampling and contact with a midwife) may work as well, or better, than current strategy of reminder invitations to non-attenders.
AIM The aim of this randomized health services study is therefore both to test the feasibility of providing alternative strategies instead of the customary reminder invitations to women in Stockholm (so-called feasibility study, primary aim), and whether such strategies will increase overall participation in screening (secondary aim).
STUDY DESIGN AND METHODOLOGY A new IT infrastructure for ordering a self-sampling kit has been developed by LabMed, KI. This in conjunction with the screening database, will be used to identify and invite women who are long-term non-participants in cervical screening. Women who have not participated for ten years, despite annual reminder invitations, will be identified and randomized to one of four strategies.
- A validated HPV self-sampling kit will be sent directly to women with a study invitation letter and instructions.
- An invitation to order an HPV self-sampling kit through an online application will be sent.
- An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent.
- The standard annual reminder invitation will be sent (control, routine practice)
Women who choose to participate will be sampled and monitored according to the standards of care in the regional cancer screening program. HPV-positive women will be followed by colposcopy and biopsy according to standard clinical guidelines. Women will be invited over the course of 3 months. All letters will be printed in advance with pre-marked dates. Batches will be sent out weekly and checked against changes in the population registry data (for individuals that have moved, taken a smear, died, or unregistered, invitation letters will be sorted out and those individuals marked in the database).
2 Notation and abbreviations
- PNR = person nummer, personal ID number 3 Study population 3.1 Inclusion criteria
- Women who have lived in Stockholm for the past 10 years and have been sent annual reminder at least once per year for 10 years without attending screening.
Specific selection process:
Include women without an "H-prov" on record for the past 10 years Include women have actively been sent a reminder invitation (invitation type=1) during 10 years time. In other words, resident in Stockholm for the past 10 years.
Include women over the age of 33 3.2 Exclusion criteria Women who have opted out of the screening program Hysterectomized Return to sender Changed PNR Women who are marked as Expired=1. Women who have reason marked for being unregistered but are not marked as is unregistered=1.
Women who are due to receive their reminder invitation in the next 3 months 4 Statistical analyses Selection of the study population Randomization A random selection of 8000 women will be chosen from all women meeting the study inclusion criteria.
These 8000 women will be randomized to the 4 study arms (age-stratified 30-50 and 51-60).
The selection of the study population and the randomization to study arms will be carried out by Anna Stoltenberg, Statistician at RCC and outside of the study group 1.
Follow-up - study end date 2016-12-31
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| HPV self sampling test sent | Active comparator | Device: Cobas PCR Female swab sample PacketA Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured. |
| HPV self sampling test ordered | Active comparator | Device: Cobas PCR Female swab sample PacketAn invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured. |
| Nurse navigator contact | Active comparator | Device: Cobas PCR Female swab sample Packet, Other: Routine practiceAn invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured |
| Control | Placebo comparator | Other: Routine practiceThe standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline. |
Who may qualify
- Ages
- 33 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Non-participants in cervical cancer screening during a 10 year period
Key exclusion criteria (1 listed)
- Active refusers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cobas PCR Female swab sample PacketThe cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected. | Device | HPV self sampling test ordered, HPV self sampling test sent, Nurse navigator contact |
| Routine practiceThe standard, annual renewed invitation to cervical screening. | Other | Control, Nurse navigator contact |
Primary outcome
Proportion of women responding (either by and HPV test or a Pap test)
Time frame: From recruitment until end of study on December 31st 2016 (average 8 months)
Participation rate in screening
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2020.
- Results publication: PubMed 31032904Elfstrom KM, Sundstrom K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Ohman D, Lamin H, Eklund C, Dillner J, Tornberg S. Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. Int J Cancer. 2019 Dec 1;145(11):3033-3039. doi: 10.1002/ijc.32374. Epub 2019 May 10.
- Derived from this study: PubMed 31522376Andersson S, Belkic K, Mints M, Ostensson E. Acceptance of Self-Sampling Among Long-Term Cervical Screening Non-Attenders with HPV-Positive Results: Promising Opportunity for Specific Cancer Education. J Cancer Educ. 2021 Feb;36(1):126-133. doi: 10.1007/s13187-019-01608-0.
- Individual participant dataSharing planned: Undecided. Our intention is to share data, but a plan for how this will be done in practise has not been written.
Related trials for Human Papillomavirus DNA Tests
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
Cervical Carcinoma, Human Papillomavirus Infection
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
Cervical Carcinoma, Human Papillomavirus Infection
Not yet recruiting
C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
Human Papillomavirus (HPV), HPV Associated Cancers
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
Cervical Carcinoma, Human Papillomavirus Infection
Active, not recruitingObservational study
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Oropharyngeal Cancer, HPV-Related Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joakim Dillner, MD principal investigator
Karolinska Institutet
Questions about this trial
What is this clinical trial studying?
A study testing Cobas PCR Female swab sample Packet and Routine practice in people with Human Papillomavirus DNA Tests and Cervical Cancer, run by Karolinska Institutet.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of women responding (either by and HPV test or a Pap test) (time frame: From recruitment until end of study on December 31st 2016 (average 8 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02750124, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2020.